Regulated information

2010 Activity Report

P_06 VÉTOQUINOL’S PROUD HISTORY
<br>
P_12 SPOTLIGHT ON INNOVATION
<br>
P_18 AN ONGOING DAILY COMMITMENT
TO VETERINARIANS
<br>
P_24 AN INTERNATIONAL COMPANY
MAINTAINING A LOCAL PRESENCE
IN GLOBAL MARKETS
<br>
P_28 GOVERNANCE AND KEY FIGURES

2010 annual earnings

Lure (France), April 4, 2011 – Vétoquinol’s Board of Directors, meeting on March 18, 2011, has reviewed the Group’s business and approved its 2010 financial statements.

2010 annual earnings Vétoquinol

Contents :
<br>> Highlights
<br>> 2010 Consolidated
Financial Statements
<br>> Strategy and Outlook
<br>> Questions and Answers

2010 Revenues grow 11.8%, driven by organic growth

The Vétoquinol Group reports sustained sales growth driven by its “hybrid” business model, supported by a sound level of organic growth.

European launch of new Nsaid Cimalgex®

Lure (France), June 14, 2011 – Vetoquinol announces the European launch of CIMALGEX®, a new treatment for pain and inflammation in dogs.

Forcyl®: european launch of new drug

Lure (France), September 29, 2011 – Vétoquinol announces the European launch of Forcyl®, a new drug based on 16% concentrated marbofloxacin allowing the treatment of cattle respiratory infections with a single injection.

International expansion and new product launches

Lure (France), July 19, 2011 – Vétoquinol Group sales rose to €139.7 million in the first six months of 2011.

Jacques du Puy appointed Vétoquinol Managing Director

Lure (France), October 12, 2011 – The Vétoquinol Group announces the appointment
of Jacques du Puy as Managing Director.

Net Sales rise 3% to €66.4 Million in the first Quarter of 2011

The Vétoquinol group reported a 3.0% rise in first quarter 2011 net sales to €66.4 million, compared to the same period last year.

Q3 2011 Sales

Vétoquinol achieved Q3 2011 sales of €68.4 million, in line with the previous year.